Rebirth of the God-level Xueba

Chapter 1491 Attitudes of researchers

“This is Sildenafil.”

“I can’t see anything.”

“You said this medicine is really interesting. A small thing can sell for hundreds of millions of dollars.”

A group of laymen surrounded the raw material of sildenafil, sighing with emotion.

The sildenafil used in clinical trials is not dyed, but pure white starch and some raw materials are used to condense into small pills, which has neither taste nor appeal.

If medical experts are discussing with each other, they can also say something new about acetylcholine.

However, in the eyes of a group of bankers who deal with money all day long, this thing looks so fictitious.

“Professor Yang is here.” Someone looked at Yang Rui and called out immediately.

Several bank cadres from Zhongnong Construction Workers straightened up immediately, showing a cordial smile.

“Professor Yang is here.”

“Congratulations on making the medicine.”

“I wish you a successful experiment.”

The cadres seemed to be paying a New Year’s greetings, and they gave up their hands and spoke auspicious words.

What everyone said is really sincere.

Although Pfizer eventually sold sildenafil to Yang Rui, it paid a high price, requiring an additional $180 million! Moreover, it is a milestone-if a finished antihypertensive drug is made, no matter if it is marketed in any country in the world, it will cost an additional 200 million U.S. dollars, and then it will be listed in Europe or the United States, and an additional 200 million U.S. dollars will be added. .

That is to say, if the anti-stress drug made of sildenafil starts to be sold in the United States, no matter how much it sells, Pfizer will have to take $580 million.

This is not over yet. If it sells well, that is, if its annual sales exceed 100 million U.S. dollars, Pfizer will take 18%-18% of sales, and convert it into profit. How can it be 20 or 30%? It’s still a milestone… If the sales exceed $1 billion and become a blockbuster, Pfizer will take 25% of the sales revenue.

It’s crazy.

To be honest, such an offer is what Pfizer can offer.

That is, Yang Rui can give it out.

Switching to a pharmaceutical company such as Zelican does not necessarily have such courage.

The highest status of the milestone is 580 million U.S. dollars, plus 25% of sales. The latter achieved sales of over 1 billion U.S. dollars, which is equivalent to an upwards of 250 million U.S. dollars a year. The patent period of 15 consecutive years is 3.8 billion. on.

A patented compound that has just passed the first clinical phase, sold for 180 million US dollars off the assembly line, and 3.8 billion upwards on the line. It is also one of the highest prices in the pharmaceutical industry that has not come in 90 years.

This is the result of Yang Rui’s struggle based on reason. Of course, in order to focus the milestone on one point of the anti-stress medicine, Yang Rui also put a little bit of water.

Nevertheless, as a compound, the price is high enough.

Even a finished drug can be sold for hundreds of millions of dollars.

Two-digit transactions are not very common.

Even foreign companies such as Zelecom rarely offer such a big milestone transaction. Like Yang Rui’s desferiprone, the milestone to the end is just the starting price of sildenafil. He still sells 7 active compounds together.

This is the case for large pharmaceutical companies, squeezing small biotech companies on the one hand, and filling the market with strong capital on the other.

If it weren’t for the background of the Chinese market, Yang Rui just wanted to get a high price.

Of course, the current high prices are not a problem for Yang Rui.

All the milestones are for the antihypertensive effect of sildenafil and not for other indications. Although Pfizer was not willing to sign such a contract, it also pinched its nose.

In fact, most medicines have additional effects. In professional terms, they can target other indications.

Simply put, the side effects of drugs can be used as new indications for drugs.

For example, the most common diarrhea.

Diarrhea is a side effect of many drugs. However, if the effect of diarrhea is good, the drugs that are prone to diarrhea can naturally be used as laxatives.

On the other hand, some medicines can cause constipation in patients, so if the effect of constipation is good, can it be made into antidiarrheal medicine?

Another example is tachycardia among the common side effects of antihypertensive drugs. For many patients, especially elderly patients, this is not good, but for patients with bradycardia, this is not a bad thing. So, da da, a drug that can treat bradycardia Fresh out, its side effect is to lower blood pressure…

In the same way, the side effect of some medicines is to lower the heart rhythm, so for patients with tachycardia, it can work again.

This shows that panacea is impossible in the age of chemical medicine.

Your medicine can not both cause diarrhea and stop diarrhea, nor can it lower blood pressure, raise blood pressure, raise heart rate, and lower heart rate.

Aspirin is already a miracle medicine. It can reduce inflammation, relieve pain and cure colds, and also inhibit platelets and prevent strokes. Even so, try to give aspirin to the nobles who suffer from hemophilia, and the other party is willing to break eight handles. Scepter, let you lose the gems above.

For pharmaceutical companies, developing a new indication for a drug is a matter of increasing profits.

Because animal experiments and clinical phase I and phase II do not need to be done, as long as its efficacy is proven in clinical phase III, the cost is relatively low.

However, not every drug is a magic drug of aspirin. There are not many drugs that can perform well in the development of new indications. Naturally, it is not easy to increase sales.

On the other hand, the patent period is not endless. The general patent period of a drug is slightly more than 15 years. The extra patent period is usually the additional patent period applied for, but it is also in single digits. In other words, it can be monopolized. There are very few patented drugs that have been sold for 25 years.

In the development of new indications, the “slightly more” part is added, which is equivalent to using follow-up costs such as clinical phase three and phase four in exchange for a single-digit increase in patent terms. It’s not cost-effective, not necessarily.

Most of the time, the development of new indications is not so much a discovery of new uses of drugs, as it is a small trick by pharmaceutical companies to extend the patent period.

Think about it further, the new indications of the drug are equivalent to side effects. The better the effect on the new indications, the stronger and more clear side effects are proved. For a drug, this is a double-edged sword. Pharmaceutical companies would rather ask for a medicine with minimal side effects and no new indications, I am afraid they are not willing to ask for a medicine with extremely strong side effects and multiple new indications.

To use the analogy of making movies, the original indication of a drug is equivalent to the theater box office, and it is the main way for the company to make money. The new indications are equivalent to the sales revenue of DVDs, Blu-ray discs, peripherals, etc. Some companies are better at these and make money through this, but after all, they are not mainstream and unstable.

Pfizer, under Yang Rui’s insistence, gave up part of the later profits and focused on the main income. It also has its own routine.

In terms of profit and loss alone, they have already made a profit since Yang Rui’s $180 million in money arrived in his account, and the rest is pure profit.

Of course, it is impossible for Yang Rui to spend 180 million US dollars in one go.

Through the coordination of several big bosses, the money was loaned by Yang Rui from the four major industrial and peasant banks in the name of Huarui Company. Each family bears a quota ranging from tens of millions, and each of them pales with horror.

Not only that, Yang Rui also has no money to give to the 200 million U.S. dollars plus 200 million U.S. dollars milestone in the later stage. The milestone that must be given to the market is that regardless of the amount of sales, the early stage can produce two or three billion U.S. dollars in annual sales of drugs. It is also rare.

Naturally, Pfizer couldn’t let the milestones it designed carefully, not to mention that Yang Rui didn’t have that much money, even if he had it. The development cycle of a drug can easily last for ten years. What should he do if he spends all his money during this period?

Therefore, China Construction Workers and Peasants has to guarantee Yang Rui.

The total amount of 580 million US dollars, in the view of the bank, they took more risks than Yang Rui.

This can be seen from the importance they attach to the Clinical Trial Center of Hedong University. The four major banks have sent a dedicated person from the headquarters to take charge of this matter. After the end of the animal experiment and clinical phase I repeated experiments, there will be a deputy general level. The cadres came to inspect.

No way, although the country has gradually gained a bit of money in the past two years it can easily afford tens of millions of dollars in funding, but the expenditure of hundreds of millions of dollars is still very powerful. It can be compared with the construction of some basic projects, such as railway, highway, bridge, telecommunications, power grid, hydropower station, and so on.

Compared with projects that are visible and tangible, and can be charged after they are built, the research and development of sildenafil is really not worrying.

Yang Rui didn’t plan to let them worry about it. He shot three consecutive shots:

“No one dares to say 100% about scientific research. We will do our best. Everyone, we must be open minded.”

“Although our clinical trial center has just been established and is relatively inexperienced, as long as we seize the opportunity, it will soon become a mature team.”

“Sidenafil’s animal experiments and the first phase of clinical trials are very good in terms of safety. In the second phase, it is a completely unfamiliar blank field. Foreigners have not done it. We are creating history every step of the way. Yes, please accompany me to witness.”

The senior cadres of several banks are going crazy.

In the past, I went to the loan company to inspect, and even if I had a meal, I would spit out some fresh abalone on my chest to prove it.

Is this attitude that you do in scientific research?

Can you be a little confident?

In the past, all loan companies made us come with confidence.

Witness the history?

Who wants to witness history?

Hundreds of millions of dollars!

Enough for many trips to Paris!

Paris……

Milan…

Long legs…

Roasted elbows…

Bikini…

Blonde……

A group of bank cadres clutched their chests and looked at the large ward behind the single-sided glass, only feeling that their blood pressure could no longer be controlled.

Genius remembers this site address in one second:. Apex novel mobile version reading URL: